The CIMP pathway, reported in the 20-30% of sporadic CRC [8], involves the serrated neoplasia pathway and mutations in KRAS 10% (usually B-Raf proto-oncogene serine/threonine kinase—BRAF—wild type) and BRAF~70% [9]. This evidence concerns the gene KRAS and colorectal carcinoma.